Pfizer tests where to inject new Weight-Loss drug for best effect
NCT ID NCT07400679
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This early-stage study tests a single dose of the experimental drug PF-08653944 in 54 overweight or obese adults. Researchers want to see how the drug is absorbed when injected into the abdomen, thigh, or upper arm. The study also monitors safety through blood tests and vital signs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PF-08653944 (also called MET097)
- What this could lead to
- If successful, this study could help determine the best injection site for future trials of this medicine for weight management.
- What could go wrong
- This is an early Phase 1 study with only 54 participants, so results may not apply to larger populations. The medicine may cause side effects like changes in blood tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
New Haven Clinical Research Unit
New Haven, Connecticut, 06511, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Can a Two-Drug combo tip the scales against obesity?